REALBOTIX CORP - ONCONETIX ACQUIRES FULL OWNERSHIP OF REALBOTIX, LLC THROUGH STOCK TRANSACTION

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: Feb 12 2026

0mins

ONCO-19.07%

Should l Buy ONCO?

Source: moomoo

Acquisition Announcement: RealBotix Corp has announced its intention to acquire 100% of RealBotix, LLC in an all-stock deal.
Strategic Move: This acquisition is part of a strategic effort to consolidate resources and enhance the company's market position in the robotics and AI sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ONCO?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ONCO

About ONCO

Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?

3 days agostocktwits

Merger Announcement: Onconetix is in the process of merging with Realbotix, a robotics company, which is expected to enhance its business focus on AI-powered humanoid robotics.
Stock Surge: Shares of Onconetix surged by 50% in pre-market trading following a 1-for-5 reverse stock split and news of the merger, indicating positive market sentiment.
Acquisition Details: The merger will give Realbotix's parent company a majority stake of up to 90% in the combined entity, with the deal expected to close in the second half of 2026.
Market Performance: Despite the surge, Onconetix shares have declined nearly 60% year-to-date, with retail sentiment remaining neutral as trading volumes increased significantly.

Onconetix Partners with Realbotix for 6G Trial

5 days agoNASDAQ.COM

6G Trial Participation: Onconetix (ONCO) announced Realbotix's involvement in Ericsson's world-first 6G over-the-air trial at its U.S. headquarters in Plano, Texas, marking Realbotix as Ericsson's first enterprise robotics client.
Real-Time Interaction Showcase: During the trial, the Realbotix robot transmitted video and interacted in real-time over Ericsson's test network, demonstrating how next-generation wireless networks can support AI robotics and real-time video streaming, highlighting the high-speed, low-latency connectivity essential for future AI-driven technologies.
AI-Agnostic Architecture: The demonstration underscored Realbotix's AI-agnostic architecture, allowing its humanoid robots to integrate with multiple AI systems, cloud platforms, and network environments, designed to enable operation across diverse ecosystems without reliance on a single AI provider.
Acquisition Agreement Progress: Onconetix previously announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, with the combined company expected to trade on Nasdaq in the second half of 2026, subject to shareholder and regulatory approvals, indicating a strategic move in the robotics sector.

Onconetix Announces 1-for-5 Reverse Stock Split

Mar 23 2026seekingalpha

Reverse Stock Split Announcement: Onconetix has announced a 1-for-5 reverse stock split effective March 25, 2026, aimed at reducing the number of outstanding shares to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
Outstanding Shares Reduction: The reverse split will decrease the company's outstanding shares from approximately 3.6 million to about 0.7 million, significantly lowering the share count in the market, which may help elevate the stock price to meet Nasdaq's listing standards.
Market Reaction: Following the announcement, Onconetix's stock price fell by 16.12% in premarket trading to $0.52, indicating a negative market response that could undermine investor confidence in the company's future prospects.
Listing Compliance Pressure: The implementation of the reverse stock split highlights the ongoing pressure the company faces to maintain its Nasdaq listing, suggesting a need for further strategic adjustments to improve its financial performance.